Recognizing the Leaky Gut as a Trans-diagnostic Target for Neuroimmune Disorders Using Clinical Chemistry and Molecular Immunology Assays. — ME/CFS Atlas
Recognizing the Leaky Gut as a Trans-diagnostic Target for Neuroimmune Disorders Using Clinical Chemistry and Molecular Immunology Assays.
Simeonova, Denitsa, Ivanovska, Mariya, Murdjeva, Mariana et al. · Current topics in medicinal chemistry · 2018 · DOI
Quick Summary
This review examines how a condition called 'leaky gut'—where the intestinal barrier becomes too permeable, allowing harmful bacteria to enter the bloodstream—may contribute to ME/CFS and other conditions affecting mood and energy. The authors summarize available blood and stool tests that can help doctors recognize leaky gut in practice. They identify specific markers (like immune responses to bacterial toxins and inflammatory proteins) that could signal intestinal barrier problems.
Why It Matters
ME/CFS patients often experience gastrointestinal dysfunction and may benefit from screening for intestinal permeability, a proposed pathogenic mechanism in the illness. This review consolidates actionable biomarkers and testing strategies that could guide personalized clinical evaluation and identify potential therapeutic targets. Understanding gut barrier integrity may help explain neuroimmune symptoms and guide symptom management in ME/CFS.
Observed Findings
Serum IgG/IgA/IgM responses to tight junction proteins (occludin and zonulin) are proposed as markers of barrier integrity loss.
Bacterial lipopolysaccharides (LPS) and IgA/IgM responses to Gram-negative gut bacteria can be detected in serum of patients with increased intestinal permeability.
Stool biomarkers including calprotectin, secretory IgA, β-defensin, and lysozyme reflect mucosal inflammation and immune defenses.
Multiple factors associated with increased gut permeability are identifiable through clinical testing: dysbiosis, SIBO, food sensitivities, infections, and psychosocial stress.
Inferred Conclusions
Leaky gut may represent a trans-diagnostic mechanism linking gut barrier dysfunction to neuroimmune disorders including ME/CFS.
Integrated assessment using blood, breath, and stool testing can systematically evaluate intestinal permeability and contributing factors in clinical practice.
Targeting factors that increase gut permeability (dysbiosis, SIBO, food sensitivities, inflammation) may represent a therapeutic avenue for neuroimmune disorders.
Remaining Questions
What is the prevalence and clinical significance of intestinal permeability specifically in ME/CFS patient populations?
Do any of these proposed biomarkers predict treatment response or clinical outcomes in ME/CFS?
What This Study Does Not Prove
This review does not establish that leaky gut causes ME/CFS or prove that treating leaky gut will resolve ME/CFS symptoms. It does not provide prevalence data for intestinal permeability in ME/CFS patients or demonstrate that specific biomarkers have clinical utility in predicting outcomes. The review is descriptive rather than experimental, so it cannot establish causal relationships.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Is leaky gut a primary driver of ME/CFS pathophysiology or a secondary consequence of other disease mechanisms?
What are the optimal cutoff values and reference ranges for these assays, and how do they vary across healthy controls and different disease populations?